Encretin Therapeutics targets the root causes of cancer and chronic disease using its proprietary Upstream–Midstream–Downstream (UMD) Framework, focusing on restoration rather than lifelong symptom management.

The platform is supported by 92 peer-reviewed studies, including 18 Nature-family publications, and a proprietary library of 83 validated pharmacological mechanisms.

Encretin is advancing over 40 indications, with an active Phase I pancreatic cancer program (Encretin-001) and multiple additional programs that are ready for rapid IND submission.

By using synergistic, low-dose drug repurposing, Encretin aims to reduce treatment toxicity and lower annual therapy costs to sustainable levels for broader patient access.

Encretin is developing therapies across oncology, neurology, metabolic, immune, and inflammatory diseases, with more than 40 validated indications in its pipeline.

Upstream Restoration targets immune dysregulation and chronic inflammation—the initiating drivers of disease—rather than only treating downstream symptoms.

Yes. All programs in the Encretin pipeline have completed mechanistic validation and are ready for rapid IND submission, enabling rapid clinical translation.

Encretin’s platform is supported by multiple core pending patents covering its unique multi-target therapeutic combinations.

Yes. Encretin actively pursues strategic partnerships for co-development, indication licensing, and global expansion to accelerate patient access worldwide.

Encretin’s focus on affordability, reduced toxicity, and functional recovery supports federal initiatives to lower drug prices and reduce the long-term healthcare burden.